Article PDF
Avoid common mistakes on your manuscript.
References
Obermeier R, Geiger R (1976) A new semisynthesis of human insulin. Hoppe-Seyler's Z Physiol Chem 357: 759–767
Markussen J (1982) Process for preparing esters of human insulin. US patent 4343898
Crea R, Kraszewski A, Hirose T, Itakura K (1978) Chemical synthesis of genes for human insulin. Proc Natl Acad Sci USA 75: 5765–5769
Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76: 106–110
Markussen J, Damgaard U, Pingel M, Snel L, Sørensen AR, Sørensen E (1983) Human insulin (Novo): chemistry and characteristics. Diabetes Care 6 (Suppl1):4–8
Change RE, Koreff EP, Hoffmann JA, Frank BH (1981) Chemical, physical, and biologic properties of biosynthetic human insulin. Diabetes Care 4: 147–154
Johnson JS (1982) Authenticity and purity of human insulin (recombinant DNA). Diabetes Care 5 (Suppl 2):4–12
Baker RS, Schmidtke JR, Ross JW, Smith WC (1981) Preliminary studies on the immunogenicity and amount of Escherichia coli polypeptides in biosynthetic human insulin produced by recombinant DNA technology. Lancet 2: 1139–1142
Keefer LM, Piron MA, DeMeyts P (1981) Human insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptors. Proc Natl Acad Sci USA 78: 1391–1395
De Meyts P, Halban P, Hepp KD (1981) In vitro studies on biosynthetic human insulin: an overview. Diabetes Care 4 (Suppl 2):144–146
Etzwiler DD (1983) International Symposium on Human Insulin: a summary. Diabetes Care 6 (Suppl 1):66–68
Skyler JS (1982) Human insulin of recombinant DNA origin: clinical potential. Diabetes Care 5 (Suppl 2):181–186
Adeniyi-Jones ROC, Jones RH, Barnes DG, Gerlis LS, Sönksen PH (1983) Porcine and human insulin (Novo): a comparison of their metabolism and hypoglycaemic activity in normal man. Diabetes Care 6 (Suppl 1):9–12
Home PD, Massi-Benedetti M, Shepherd GAA, Hanning I, Alberti KGMM, Owens DR (1982) A comparison of the activity and disposal of semisynthetic human and porcine insulin in normal man by the glucose clamp technique. Diabetologia 22: 41–45
Massi-Benedetti M, Burrin JM, Capaldo B, Alberti KGMM (1982) A comparative study of the activity of biosynthetic human insulin and pork insulin using the glucose clamp technique in normal subjects. Diabetes Care 5 (Suppl 2):163–167
Szekeres A, Worcester B, Ascher MS, Tuxen D, Heyendal R, Walsh KM, Charles MA (1983) Comparison of the biologic activity of porcine and semisynthetic human insulins using the glucosecontrolled insulin infusion system in insulin-dependent diabetes. Diabetes Care 6: 183–196
Charles MA, Szekeres A, Staten M, Worcester B, Walsh KM (1983) Comparison of porcine insulin and human insulin (Novo) using the glucose-controlled insulin infusion system, glucose-insulin dose-response curves, and the outpatient effectiveness of human insulin (Novo) in insulin-dependent diabetes. Diabetes Care 6 (Suppl 1):29–34
Howey DC, Fineberg SE, Nolen PA, Stone MI, Gibson RG, Fineberg NS, Galloway JA (1982) The therapeutic efficacy of human insulin (recombinant DNA) in patients with insulin-dependent diabetes mellitus. Diabetes Care 5 (Suppl 2):73–77
Kemmer FW, Sonnenberg GE, Cüppers HJ, Berger M (1982) Absorption kinetics of semisynthetic human insulin and biosynthetic (recombinant DNA) human insulin. Diabetes Care 5 (Suppl 2):23–28
Owens DR, Jones MK, Birtwell AJ, Jones JR, Hayes TM, Heding LG (1983) The clinical pharmacology of human insulin (Novo) in normal subjects. Diabetes Care 6 (Suppl 1): 13–16
Waldhäusl WK, Bratusch-Marrain PR, Vierhapper H, Nowotny P (1983) Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man. Metabolism 32: 478–486
Galloway JA, Root MA, Bergstrom R, Spradlin C, Howey DC, Fineberg SE, Jackson RL (1982) Clinical pharmacology studies with human insulin (recombinant DNA). Diabetes Care 5 (Suppl 2):13–22
Chawdhury SA, Dodson EJ, Dodson GG, Reynolds CD, Tolley SP, Blundell TL, Cleasby A, Pitts JE, Tickle IJ, Wood SP (1983) The crystal structures of three non-pancreatic human insulins. Diabetologia 25: 460–464
Sonnenberg GE, Chantelau E, Sundermann S, Hauff C, Berger M (1982) Human and porcine regular insulins are equally effective in subcutaneous replacement therapy. Results of a double-blind crossover study in Type-I diabetic patients with continuous subcutaneous insulin infusion. Diabetes 31: 600–602
Clark AJL, Knight G, Wiles PG, Keen H, Ward JD, Cauldwell JM, Adeniyi-Jones RO, Leiper JM, Jones RH, MacCuish AC, Watkins PJ, Glynne A (1982) Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet 1: 354–357
Galloway JA, Peck FB, Jr., Fineberg SE, Spradlin CT, Marsden JH, Allemenos D, Ingulli-Fattic J (1982): The US “New Patient” and “Transfer” studies. Diabetes Care 5 (Suppl 2):135–139
Petersen KG, Schlüter KJ, Kerp L (1982) Less pronounced changes in serum potassium and epinephrine during hypoglycaemia induced by human insulin (recombinant DNA). Diabetes Care 5 (Suppl 2):90–92
Schlüter KJ, Petersen KG, Sontheimer J, Enzmann F, Kerp L (1982) Different counterregulatory responses to human insulin (recombinant DNA) and purified pork insulin. Diabetes Care 5 (Suppl 2):78–81
Rosak C, Althoff PH, Enzmann F, Schöffling K (1982) Comparative studies on intermediary metabolism and hormonal counterregulation following human insulin (recombinant DNA) and purified pork insulin in man. Diabetes Care 5 (Suppl 2):82–89
Müller-Esch G, Ball P, Bekemeyer U, Heidbüchel K, Kraas E, Wood W, Scriba WG (1983) Vergleich einer hormonellen und metabolischen Gegenregulation beim GCIIS-gesteuerten Insulinhypoglykärnietest mit biosynthetischem Humaninsulin und Schweineinsulin. Akt Endokrinol 4: 100 (Abstract)
Fineberg SE, Galloway YA, Fineberg NS, Rathbun MJ (1982) Immunologic improvement resulting from the transfer of animalinsulin-treated diabetic subjects to human insulin (recombinant DNA). Diabetes Care 5 (Suppl 2):107–113
Fireman P, Fineberg SE, Galloway JA (1982) Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care 5 (Suppl 2):119–125
Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S (1983) Immunogenicity of human insulin of recombinant DNA origin. Diabetologia 25: 465–469
Carveth-Johnson AO, Mylvaganam K, Child DF (1982) Generalised allergic reaction with synthetic human insulin. Lancet 2: 1287 (Letter)
Mühlhauser J, Jörgens V, Berger M, Graninger W, Gürtler W, Hornke L, Kunz A, Schernthaner G, Scholz V, Voss HE (1983) Bicentric evaluation of a teaching and treatment programme for Type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia 25: 470–476
Science Research News (1983) Dietary dogma disproved. Science 220: 487–488
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sonnenberg, G.E., Berger, M. Human insulin: Much ado about one amino acid?. Diabetologia 25, 457–459 (1983). https://doi.org/10.1007/BF00284450
Issue Date:
DOI: https://doi.org/10.1007/BF00284450